Browse by UCL Departments and Centres
 | Up a level |
Group by: Author | Type
Number of items: 17.
A
|
Ainley, L;
Chavda, SJ;
Counsell, N;
Cheesman, S;
Newrick, F;
Horder, J;
Kyriakou, C;
... Yong, K; + view all
(2021)
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
British Journal of Haematology
, 192
(3)
e73-e77.
10.1111/bjh.17248.
|
|
Arend, RC;
Monk, BJ;
Herzog, TJ;
Moore, KN;
Shapira-Frommer, R;
Ledermann, JA;
Tewari, KS;
... Penson, RT; + view all
(2021)
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecologic Oncology
10.1016/j.ygyno.2021.02.014.
(In press).
|
B
|
Baert, T;
Ferrero, A;
Sehouli, J;
O Donnell, DM;
González-Martín, A;
Joly, F;
Van der Velden, J;
... Ledermann, JA; + view all
(2021)
The systemic treatment of recurrent ovarian cancer revisited.
Annals of Oncology
10.1016/j.annonc.2021.02.015.
(In press).
|
C
Camilleri, M;
Cuadrado, M;
Phillips, E;
Wilson, W;
Jenner, R;
Pang, G;
Kamora, S;
... Yong, K; + view all
(2021)
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
British Journal of Haematology
10.1111/bjh.17377.
(In press).
|
 |
|
Camilleri, M;
Sive, J;
Wilson, W;
Pang, G;
Jenner, R;
Phillips, E;
Popat, R;
... Yong, K; + view all
(2021)
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
British Journal of Haematology
, 192
(1)
E14-E16.
10.1111/bjh.17168.
|
|
Concin, N;
Creutzberg, CL;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, JA;
... Matias-Guiu, X; + view all
(2021)
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Virchows Archiv
, 478
pp. 153-190.
10.1007/s00428-020-03007-z.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
International Journal Of Gynecological Cancer
, 31
(1)
pp. 12-39.
10.1136/ijgc-2020-002230.
|
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Radiotherapy and Oncology
, 154
pp. 327-353.
10.1016/j.radonc.2020.11.018.
|
|
Cross, AJ;
Myles, J;
Greliak, P;
Hackshaw, A;
Halloran, S;
Benton, SC;
Addison, C;
... Raine, R; + view all
(2021)
Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial.
Journal of Medical Screening
10.1177/0969141321997480.
|
|
D
|
Dettorre, GM;
Dolly, S;
Loizidou, A;
Chester, J;
Jackson, A;
Mukherjee, U;
Zambelli, A;
... OnCovid study group, ; + view all
(2021)
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score.
Journal for ImmunoTherapy of Cancer
, 9
(3)
, Article e002277. 10.1136/jitc-2020-002277.
|
|
K
|
Kurtz, JE;
Gebski, V;
Sukhin, V;
Carey, M;
Kong, I;
Glasspool, RM;
Berek, JS;
... Friedlander, M; + view all
(2021)
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecologic Oncology
10.1016/j.ygyno.2021.02.018.
(In press).
|
L
|
Ledermann, JA;
Embleton-Thirsk, AC;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
Hirte, H;
... ICON6 collaborators, .; + view all
(2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
ESMO Open
, 6
(2)
, Article 100043. 10.1016/j.esmoop.2020.100043.
|
|
|
Lee, CK;
Friedlander, ML;
Tjokrowidjaja, A;
Ledermann, JA;
Coleman, RL;
Mirza, MR;
Matulonis, UA;
... Scott, CL; + view all
(2021)
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
10.1002/cncr.33517.
(In press).
|
M
|
McCulloch, R;
Lewis, D;
Crosbie, N;
Eyre, TA;
Bolam, S;
Arasaretnam, A;
Creasey, T;
... Rule, S; + view all
(2021)
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
British Journal of Haematology
10.1111/bjh.17363.
|
|
P
|
Popat, R;
Counsell, N;
de Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, JD;
Adedayo, T;
... Yong, K; + view all
(2021)
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
British Journal of Haematology
10.1111/bjh.17391.
(In press).
|
|
Poveda, A;
Floquet, A;
Ledermann, JA;
Asher, R;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 investigators, .; + view all
(2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncology
10.1016/S1470-2045(21)00073-5.
(In press).
|
R
|
Russell, J;
Collins, A;
Fowler, A;
Karanth, M;
Saha, C;
Docherty, S;
Padayatty, J;
... Follows, GA; + view all
(2021)
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Annals of Hematology
, 100
pp. 1049-1058.
10.1007/s00277-021-04460-9.
|
|
